Cargando…
Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis
OBJECTIVE: This meta-analysis aimed to investigate the efficacy and safety of pentoxifylline (PTF) plus angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for proteinuria and kidney function in chronic kidney disease (CKD). METHODS: CENTRAL, EMBASE, Ovid-MEDLINE, P...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536675/ https://www.ncbi.nlm.nih.gov/pubmed/28415944 http://dx.doi.org/10.1177/0300060516663094 |
_version_ | 1783254060368920576 |
---|---|
author | Liu, Dong Wang, Li-na Li, Hong-xia Huang, Ping Qu, Liang-bo Chen, Fei-yan |
author_facet | Liu, Dong Wang, Li-na Li, Hong-xia Huang, Ping Qu, Liang-bo Chen, Fei-yan |
author_sort | Liu, Dong |
collection | PubMed |
description | OBJECTIVE: This meta-analysis aimed to investigate the efficacy and safety of pentoxifylline (PTF) plus angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for proteinuria and kidney function in chronic kidney disease (CKD). METHODS: CENTRAL, EMBASE, Ovid-MEDLINE, PubMed, and CNKI were searched for relevant, randomized, controlled trials (RCTs). A meta-analysis was performed to review the effect of PTF plus ACEIs/ARBs vs. ACEIs/ARBs alone on proteinuria and kidney function in CKD. RESULTS: Eleven RCTs including 705 patients were retrieved. PTF plus ACEI/ARB treatment significantly decreased proteinuria in patients with CKD within 6 months (standard mean difference [SMD] −0.52; 95% CI −0.90 to 0.15; I(2 )= 68%) and significantly attenuated a decrease in estimated glomerular filtration rate (eGFR) in patients with stages 3–5 CKD after 6 months of treatment (standard mean difference [SMD] 0.30; confidence limit [Cl] 95% CI 0.06 to 0.54; I(2 )= 0%). PTF plus ACEIs/ARBs for 9 to 12 months significantly reduced albuminuria in patients with CKD (SMD−0.30, 95% CI −0.57 to 0.03; I(2 )= 0%) and alleviated the decline in eGFR in patients with stages 3–5 CKD (SMD 0.51; 95% CI 0.06 to 0.96; I(2 )= 61%). CONCLUSION: The combination of an ACEI or ARB and PTF has a protective effect in reducing proteinuria by ameliorating the decline in eGFR in patients with stages 3–5 CKD. |
format | Online Article Text |
id | pubmed-5536675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-55366752017-10-03 Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis Liu, Dong Wang, Li-na Li, Hong-xia Huang, Ping Qu, Liang-bo Chen, Fei-yan J Int Med Res Meta-Analysis OBJECTIVE: This meta-analysis aimed to investigate the efficacy and safety of pentoxifylline (PTF) plus angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for proteinuria and kidney function in chronic kidney disease (CKD). METHODS: CENTRAL, EMBASE, Ovid-MEDLINE, PubMed, and CNKI were searched for relevant, randomized, controlled trials (RCTs). A meta-analysis was performed to review the effect of PTF plus ACEIs/ARBs vs. ACEIs/ARBs alone on proteinuria and kidney function in CKD. RESULTS: Eleven RCTs including 705 patients were retrieved. PTF plus ACEI/ARB treatment significantly decreased proteinuria in patients with CKD within 6 months (standard mean difference [SMD] −0.52; 95% CI −0.90 to 0.15; I(2 )= 68%) and significantly attenuated a decrease in estimated glomerular filtration rate (eGFR) in patients with stages 3–5 CKD after 6 months of treatment (standard mean difference [SMD] 0.30; confidence limit [Cl] 95% CI 0.06 to 0.54; I(2 )= 0%). PTF plus ACEIs/ARBs for 9 to 12 months significantly reduced albuminuria in patients with CKD (SMD−0.30, 95% CI −0.57 to 0.03; I(2 )= 0%) and alleviated the decline in eGFR in patients with stages 3–5 CKD (SMD 0.51; 95% CI 0.06 to 0.96; I(2 )= 61%). CONCLUSION: The combination of an ACEI or ARB and PTF has a protective effect in reducing proteinuria by ameliorating the decline in eGFR in patients with stages 3–5 CKD. SAGE Publications 2017-03-06 2017-04 /pmc/articles/PMC5536675/ /pubmed/28415944 http://dx.doi.org/10.1177/0300060516663094 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Meta-Analysis Liu, Dong Wang, Li-na Li, Hong-xia Huang, Ping Qu, Liang-bo Chen, Fei-yan Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
title | Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
title_full | Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
title_fullStr | Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
title_full_unstemmed | Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
title_short | Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
title_sort | pentoxifylline plus aceis/arbs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536675/ https://www.ncbi.nlm.nih.gov/pubmed/28415944 http://dx.doi.org/10.1177/0300060516663094 |
work_keys_str_mv | AT liudong pentoxifyllineplusaceisarbsforproteinuriaandkidneyfunctioninchronickidneydiseaseametaanalysis AT wanglina pentoxifyllineplusaceisarbsforproteinuriaandkidneyfunctioninchronickidneydiseaseametaanalysis AT lihongxia pentoxifyllineplusaceisarbsforproteinuriaandkidneyfunctioninchronickidneydiseaseametaanalysis AT huangping pentoxifyllineplusaceisarbsforproteinuriaandkidneyfunctioninchronickidneydiseaseametaanalysis AT quliangbo pentoxifyllineplusaceisarbsforproteinuriaandkidneyfunctioninchronickidneydiseaseametaanalysis AT chenfeiyan pentoxifyllineplusaceisarbsforproteinuriaandkidneyfunctioninchronickidneydiseaseametaanalysis |